Stem cell characteristics of cell sub-populations in cell lines derived from head and neck cancers of Fanconi anemia patients

Journal of Oral Pathology and Medicine

Volumn 40, Issue 2, 2011, Pages 143-152

  Gammon, Luke ^a,b   Biddle, Adrian ^a   Fazil, Bilal ^a   Harper, Lisa ^a   Mackenzie, Ian C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Apoptosis; Cell cycle; Fanconi anemia; HNSCC; Stem cells

Indexed keywords

DNA; FANCONI ANEMIA PROTEIN; HERMES ANTIGEN; MITOMYCIN C;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL CULTURE; CELL CYCLE G2 PHASE; CELL STRUCTURE; CELL SUBPOPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; ULTRAVIOLET B RADIATION;

ANTIGENS, CD44; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASTIC STEM CELLS;

EID: 79251568305     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00972.x     Document Type: Article

References (56)

1. Kennedy RD, D'andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005; 19: 2925-40.
2. Taniguchi T, D'andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006; 107: 4223-33.
3. Van Zeeburg HJ, Snijders PJ, Pals G, et al. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res 2005; 65: 1271-6.
4. Patel KJ, Joenje H. Fanconi anemia and DNA replication repair. DNA Repair (Amst) 2007; 6: 885-90.
5. Taniguchi T, Dandrea AD. Molecular pathogenesis of fanconi anemia. Int J Hematol 2002; 75: 123-8.
6. Alter BP. Fanconis anemia, transplantation and cancer. Pediatr Transplant 2005; 9: 81-6.
7. Tudor D, Locke M, Owen-Jones E, et al. Intrinsic patterns of behavior of epithelial stem cells. J Investig Dermatol Symp Proc 2004; 9: 208-14.
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
9. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
10. Al Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23: 7274-82.
11. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
12. Tsai RY. A molecular view of stem cell and cancer cell self-renewal. Int J Biochem Cell Biol 2004; 36: 684-94.
13. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays 2009; 31: 1038-49.
14. Al Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
15. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
16. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973-8.
17. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
19. Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
20. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10(920): R25.
21. Harper LJ, Costea DE, Gammon L, et al. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 2010; 10: 166-82.
22. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007; 19: 61-4.
23. Sell S. Cancer stem cells and differentiation therapy. Tumour Biol 2006; 27: 59-70.
24. Hombach-Klonisch S, Paranjothy T, Wiechec E, et al. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp (Warsz) 2008; 56: 165-80.
25. Harper LJ, Piper K, Common J, et al. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007; 36: 594-603.
26. Locke M, Heywood M, Fawell S, et al. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005; 65: 8944-50.
27. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007; 67: 6796-805.
28. Gao Z, Mackenzie IC. Influence of retinoic acid on the expression of cytokeratins, vimentin and ICAM-1 in human gingival epithelia in vitro. J Periodontal Res 1996; 31: 81-9.
29. Gao Z, Mackenzie IC. Patterns of phenotypic expression of human junctional, gingival and reduced enamel epithelia in vivo and in vitro. Epithelial Cell Biol 1992; 1: 156-67.
30. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
31. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008; 14: 4085-95.
32. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-19.
33. Zhang Q, Shi S, Yen Y, et al. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 2009; 289: 151-60.
34. Chen CY, Chiou SH, Huang CY, et al. Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model. J Biomed Sci 2009; 16: 100.
35. Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol 2010; 46: 158-65.
36. Chen YC, Chen YW, Hsu HS, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009; 385: 307-13.
37. Hayry V, Makinen LK, Atula T, et al. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer 2010; 102: 892-7.
38. Okamoto A, Chikamatsu K, Sakakura K, et al. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 2009; 45: 633-9.
39. Yajima T, Ochiai H, Uchiyama T, et al. Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol 2009; 35: 273-80.
40. Zhang P, Zhang Y, Mao L, et al. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett 2009; 277: 227-34.
41. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 2004; 91: 223-31.
42. Balz V, Scheckenbach K, Gotte K, et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens Cancer Res 2003; 63: 1188-91.
43. Kruyt FA, Dijkmans LM, Dijkmans LM, et al. Involvement of the Fanconi's anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase. Cancer Res 1997; 57: 2244-51.
44. Kruyt FA, Dijkmans LM, Arwert F, et al. Involvement of the Fanconi's anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase. Cancer Res 1997; 57: 2244-51.
45. Van Der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11: 7508-15.
46. Rathbun RK, Faulkner GR, Ostroski MH, et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 1997; 90: 974-85.
47. Cumming RC, Liu JM, Youssoufian H, et al. Suppression of apoptosis in hematopoietic factor-dependent progenitor cell lines by expression of the FAC gene. Blood 1996; 88: 4558-67.
48. Otsuki T, Nagakura S, Wang J, et al. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J Cell Physiol 1999; 179: 79-86.
49. Kachnic LA, Li L, Fournier L, et al. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 2010; 292: 73-9.
50. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-54.
51. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008; 26: 2871-5.
52. Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 2009; 42: 31-8.
53. Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 2008; 11: 110-21.
54. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009; 23: 285-91.
55. Hoey T, Yen WC, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5: 168-77.
56. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-59.